13F Holdings
中文EN

VYGR Voyager Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1640266 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-19.8%
TTM net income YoY17.6%
TTM EPS YoY19.8%
Revenue 3-yr CAGR-45.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-450.1%
Net margin-416.3%
FCF margin-437.4%
EBITDA margin-435.3%

Returns

ROE-58.9%
ROA-44.9%
ROIC (approx.)-69.8%
Asset turnover0.11x

Leverage & solvency

Liabilities / assets23.7%
Debt / equity0.00x
Current ratio6.81x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.04x
Accruals ratio2.0%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$40.37M$80.00M$250.01M$40.91M$37.41M
R&D expense$134.67M$127.37M$92.17M$60.76M$73.79M
SG&A expense$37.54M$35.92M$35.82M$30.98M$37.25M
Operating income-$131.84M-$83.29M$122.01M-$50.84M-$73.62M
Pretax income-$119.58M-$64.34M$133.74M-$46.39M-$71.20M
Income tax$144,000$665,000$1.41M$16,000—
Net income-$119.72M-$65.00M$132.33M-$46.41M-$71.20M
EBITDA-$127.78M-$78.56M$126.45M-$44.65M-$68.45M
EPS (basic)-2.04-1.133.08-1.21-1.89
EPS (diluted)-2.04-1.132.97-1.21-1.89
Dividends declared per share————0.00
Weighted avg. shares (diluted)58.69M57.67M44.57M38.36M37.67M
Balance sheet
Cash & equivalents$65.30M$74.24M$70.39M$100.47M$119.21M
Short-term investments$131.15M$195.32M$162.07M$19.89M$15.11M
Receivables$1.76M$1.50M$80.15M——
Current assets$202.69M$276.81M$319.68M$124.50M$136.70M
PP&E, net$13.14M$14.31M$16.49M$17.86M$21.92M
Total assets$252.28M$393.05M$351.28M$159.36M$193.85M
Current liabilities$26.54M$49.79M$64.51M$72.59M$50.98M
Total liabilities$56.20M$93.29M$114.96M$100.34M$98.80M
Shareholders' equity$196.08M$299.76M$236.32M$59.02M$95.06M
Shares outstanding59.05M54.73M44.04M38.61M37.92M
Cash flow statement
Operating cash flow-$132.47M-$15.31M$77.92M-$12.51M-$53.52M
Capital expenditure$2.60M$3.52M$3.26M$2.49M$1.61M
Free cash flow-$135.06M-$18.83M$74.66M-$15.00M-$55.13M
Investing cash flow$125.45M-$94.86M-$141.64M-$7.34M$65.91M
Financing cash flow$816,000$114.02M$33.65M$1.11M$612,000
Depreciation & amortization$4.06M$4.73M$4.44M$6.19M$5.17M
Stock-based compensation$14.79M$14.79M$11.15M$9.34M$11.32M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.